Tiotropium bromide vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT02172287 · Phase 3 · completed
This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).
Reported efficacy
Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)
Result source: NCT02172287
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Reported efficacy
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)
Result source: NCT02184611
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tiotropium bromide | Umeclidinium |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.9 vs 1.3−0.4 vs placeboNCT016639871 other result
| —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs 0.1vs ABNCT0279667742 other results
| 0.1 vs -0.0+0.2 vs placeboNCT0218461121 other results
|
| SGRQ total, change | -4.1 vs -2.0−2.1 vs placeboNCT00496470 | -6.2 vs -2.1−4 vs placeboNCT021526055 other results
|
| TDI focal score | —Not posted · NCT02172287 | 2.5 vs 1.6+0.9 vs placeboNCT02184611 |
Moderate or severe exacerbations, annualised rate
- Tiotropium bromide
- 0.9 vs 1.3−0.4 vs placeboNCT01663987
1 other result
- 0.9 vs 1.3 NCT01662986
- Umeclidinium
- —Trial running · NCT06474039
Trough FEV1, change
- Tiotropium bromide
- 0.1 vs 0.1vs ABNCT02796677
42 other results
- 0.2 vs -0.1 NCT01663987
- 0.2 vs 0.1 NCT01662986
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.1 vs 0.1 NCT03118765
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00359788
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.0 NCT00528996
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.1 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.1 vs -0.0 NCT00523991
- 0.2 vs 0.0 NCT01663987
- 0.2 vs 0.0 NCT01662986
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.0 vs 0.0 NCT00528996
- 0.1 vs 0.0 NCT00528996
- 0.1 vs -0.0 NCT00359788
- Umeclidinium
- 0.1 vs -0.0+0.2 vs placeboNCT02184611
21 other results
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT02119286
- 0.1 vs -0.0 NCT02119286
- 0.2 vs 0.1 NCT02207829
- 0.2 vs 0.2 NCT02257385
- 0.1 vs 0.1 NCT02729051
- 0.2 vs 0.0 NCT02152605
- 0.2 vs 0.1 NCT01879410
- 0.1 vs -0.0 NCT02257372
- 0.1 vs -0.0 NCT03034915
- 0.1 vs 0.1 NCT02236611
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.2 vs -0.0 NCT02275052
SGRQ total, change
- Tiotropium bromide
- -4.1 vs -2.0−2.1 vs placeboNCT00496470
- Umeclidinium
- -6.2 vs -2.1−4 vs placeboNCT02152605
5 other results
- -7.0 vs -2.5 NCT02184611
- -5.8 vs -1.4 NCT02184611
- -7.3 vs -4.3 NCT02184611
- -5.8 vs -4.9 NCT02729051
- -5.0 vs -3.3 NCT03034915
TDI focal score
- Tiotropium bromide
- —Not posted · NCT02172287
- Umeclidinium
- 2.5 vs 1.6+0.9 vs placeboNCT02184611
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Tiotropium bromide: 5 of 5 rows · Umeclidinium: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tiotropium bromide Rows use multiple source trials | Umeclidinium Rows use multiple source trials |
|---|---|---|
| FEV1 Change 3 h absolute change · L | 0.2 vs -0.05 placebo L @ 24wka,b,c,d NCT00523991 · Phase 4 · registry result, not featured evidence | 0.052 vs 0.048 FF L @ 4wk100/250 µge,a,b,c,d NCT02164539 · Phase 2 · registry result, not featured evidence · combination show 3 more doses0.072 vs 0.048 FF L @ 4wk100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0.093 vs 0.048 FF L @ 4wk100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0.088 vs 0.048 FF L @ 4wk100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 10.3%50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 15%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 33.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 11.3% NCT00523991 · Phase 4 · registry result, not featured evidence 7.9% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 13.3% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 0%18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 23.2%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 23.4%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 13.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 16.1%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 6.3%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination | 13.7%62.5 mcgg NCT02184611 · Phase 3 show 25 more results8.9%125 µg QD NCT01772147 · Phase 3 · combination 12.3%62.5 µg QD NCT01772147 · Phase 3 · combination 5.3%62.5 µg NCT01957163 · Phase 3 · combination 8.7%125 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT02119286 · Phase 3 · combination 5.3%62.5 µg NCT02119286 · Phase 3 · combination 10.7%125 µg QD NCT01772134 · Phase 3 · combination 6.9%62.5 µg QD NCT01772134 · Phase 3 · combination 11.7%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 5%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 8.4%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 8.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.6%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 7.3%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 6.4%50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results—50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination —18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 10.3%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence —50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence —50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT00523991 · Phase 4 · registry result, not featured evidence 2.4% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence — NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 10.6%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 11.1%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 10.5%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence —150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 3.3%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.2%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 3.1%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence —5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination | 2.4%62.5 mcgg NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 4.9%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 1.9%125 µg NCT01957163 · Phase 3 · combination 1%125 µg NCT02119286 · Phase 3 · combination 3.4%62.5 µg NCT02119286 · Phase 3 · combination 4.9%125 µg QD NCT01772134 · Phase 3 · combination 2.5%62.5 µg QD NCT01772134 · Phase 3 · combination 3.6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 1.9%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5.9%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 2%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 2.5%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | —50/250 µg BIDf NCT01762800 · Phase 4 · registry result, not featured evidence show 37 more results5.9%50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence 8.8%50/250 µg BID + 18 µg QD NCT01762800 · Phase 4 · registry result, not featured evidence · combination 10.7%18 µg QD + 50/250 µg BID NCT01762800 · Phase 4 · registry result, not featured evidence · combination 37.5%18μg NCT01663987 · Phase 4 · registry result, not featured evidence 25.6%18 μg NCT01662986 · Phase 4 · registry result, not featured evidence 0%50/250 µg BID NCT01751113 · Phase 4 · registry result, not featured evidence 3.8%50/250 µg BID + 18 µg QD NCT01751113 · Phase 4 · registry result, not featured evidence · combination 4.2% NCT00523991 · Phase 4 · registry result, not featured evidence 3% NCT00496470 · Phase 4 · registry result, not featured evidence · combination 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 0% NCT03137992 · Phase 3 · registry result, not featured evidence —5 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence —18 mcg NCT02683668 · Phase 3 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 32.9%5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.9%18 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 33.8%2.5 mcg NCT01126437 · Phase 3 · registry result, not featured evidence 0%150 μg NCT00999908 · Phase 3 · registry result, not featured evidence 0%10 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%40 μg NCT03118765 · Phase 2 · registry result, not featured evidence 0%20 μg NCT03118765 · Phase 2 · registry result, not featured evidence 2%5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%18 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 1.4%1.25 mcg NCT01222533 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination | 8.3%62.5 mcgg NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 3%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT01957163 · Phase 3 · combination 1.4%125 µg NCT02119286 · Phase 3 · combination 3.9%62.5 µg NCT02119286 · Phase 3 · combination 2.9%125 µg QD NCT01772134 · Phase 3 · combination 2%62.5 µg QD NCT01772134 · Phase 3 · combination 6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence 3%62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.4%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence 6.9%62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence 1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 50/250 µg BIDf nasopharyngitis 18.4% dysphonia 13.2% bronchitis 5.1% NCT01762800 · Phase 4 · registry result, not featured evidence show 27 more results50/250 µg BID + 18 µg QD nasopharyngitis 20.6% bronchitis 10.3% dysphonia 8.8% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18 µg QD + 50/250 µg BID nasopharyngitis 26.7% dysphonia 8% bronchitis 6.7% NCT01762800 · Phase 4 · registry result, not featured evidence · combination 18μg chronic obstructive pulmonary disease 37.5% (placebo 43.6%) bronchitis 7.5% (placebo 5.1%) insomnia 5% (placebo 5.1%) NCT01663987 · Phase 4 · registry result, not featured evidence 18 μg chronic obstructive pulmonary disease 25.6% (placebo 15.4%) contusion 7.7% (placebo 0%) oedema peripheral 7.7% (placebo 0%) NCT01662986 · Phase 4 · registry result, not featured evidence 50/250 µg BID dysphonia 5.9% constipation 2% dry mouth 2% NCT01751113 · Phase 4 · registry result, not featured evidence 50/250 µg BID + 18 µg QD dysphonia 9.6% nasopharyngitis 5.8% arthralgia 3.8% NCT01751113 · Phase 4 · registry result, not featured evidence · combination nasophayngitis 6.7% (placebo 5%) chronic obstructive pulmonary disease 4.6% (placebo 9.6%) NCT00523991 · Phase 4 · registry result, not featured evidence chronic obstructive pulmonary disease 6.4% NCT00359788 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 32.9% NCT01126437 · Phase 3 · registry result, not featured evidence 18 mcg chronic obstructive pulmonary disease 33.9% NCT01126437 · Phase 3 · registry result, not featured evidence 2.5 mcg chronic obstructive pulmonary disease 33.8% NCT01126437 · Phase 3 · registry result, not featured evidence 10 μg cough 3.3% (placebo 0%) headache 3.3% (placebo 3%) urinary tract infection 3.3% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 40 μg dry mouth 12.9% (placebo 0%) dizziness 3.2% (placebo 6.1%) back pain 0% (placebo 3%) NCT03118765 · Phase 2 · registry result, not featured evidence 20 μg back pain 6.3% (placebo 3%) headache 6.3% (placebo 3%) cough 3.1% (placebo 0%) NCT03118765 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 9.3% (placebo 4.1%) dyspnoea 2% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 18 mcg nasopharyngitis 4.8% (placebo 4.1%) dyspnoea 2.1% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 2.5 mcg dyspnoea 1.4% (placebo 9.5%) nasopharyngitis 1.4% (placebo 4.1%) NCT01222533 · Phase 2 · registry result, not featured evidence 1.25 mcg nasopharyngitis 6.1% (placebo 4.1%) dyspnoea 3.4% (placebo 9.5%) NCT01222533 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination | 62.5 mcgg upper respiratory tract infection 12.2% (placebo 12.9%) nasopharyngitis 9.3% (placebo 10.9%) dizziness 2.9% (placebo 2%) NCT02184611 · Phase 3 show 23 more results125 µg QD nasopharyngitis 5% (placebo 4.5%) headache 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.5%) nasopharyngitis 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg headache 4.4% (placebo 2.9%) back pain 3.4% (placebo 1.5%) nasopharyngitis 3.4% (placebo 3.4%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 4.8% (placebo 3.4%) headache 4.3% (placebo 2.9%) cough 3.4% (placebo 0.5%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 9.2% (placebo 10.7%) headache 1.9% (placebo 2.4%) back pain 1% (placebo 1.9%) NCT02119286 · Phase 3 · combination 62.5 µg nasopharyngitis 5.3% (placebo 10.7%) back pain 3.9% (placebo 1.9%) headache 3.9% (placebo 2.4%) NCT02119286 · Phase 3 · combination 125 µg QD headache 6.3% (placebo 4.9%) cough 2.4% (placebo 1.5%) nasopharyngitis 2.4% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.9%) cough 3.4% (placebo 1.5%) nasopharyngitis 2.5% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 mcg QD headache 8.1% nasopharyngitis 8.1% NCT02236611 · Phase 4 · registry result, not featured evidence 62.5 mcg+ICS/LABA nasopharyngitis 13.4% (placebo 14.5%) headache 3.4% (placebo 6.8%) cough 2.5% (placebo 4.3%) NCT02257372 · Phase 4 · registry result, not featured evidence · combination 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence 62.5 mcg QD headache 5.9% nasopharyngitis 5.3% NCT02207829 · Phase 3 · registry result, not featured evidence 62.5/25 µg headache 7.5% nasopharyngitis 6.6% cough 3.3% NCT02257385 · Phase 3 · registry result, not featured evidence 62.5/25mcg headache 6.5% (placebo 6.5%) nasopharyngitis 5.2% (placebo 6.5%) NCT02152605 · Phase 3 · registry result, not featured evidence 62.5/25 mcg headache 6.9% nasopharyngitis 4% NCT01879410 · Phase 3 · registry result, not featured evidence 62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 4 versus Phase 2.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 24 weeks versus 4 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tiotropium bromide
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
+ 113 further endpoints in the CSV export.
Umeclidinium
show 10 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 4 more results
show 1 more result
+ 12 further endpoints in the CSV export.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT00772538 · Phase 3 · completed
The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.
Next expected readout: January 2027 · NCT06679465 (registry estimate)
Reported efficacy
Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)
Result source: NCT00772538
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT01573624 · Phase 2 · completed
The study randomized 421 participants to three 14-day treatment periods and kept participants and investigators blinded, with active comparator arms. Its primary outcomes were lung-function measures rather than hard clinical outcomes, and the results were mixed: trough FEV1 was significantly higher with the 125- and 250-mcg UMEC doses but not with the lower doses.
Reported efficacy
Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period); Percentage of Chance That FF 100 mcg Alone Corrected Change From Baseline FEV1 Response Would Exceed a Target Response by Dose of UMEC Combined With FF 100 mcg (Baseline (Day 1) and Day 15 of each treatment period); Mean Change From Baseline in Trough FEV1 on Day 15 of Each of the 3 Treatment Periods (Baseline (Day 1) and Day 15 of each treatment period): Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873) (mixed)
Result source: NCT01573624
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Tiotropium bromide | Umeclidinium |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Trial running · NCT04651777 |
| Trough FEV1, change | 0.1 vs -0.0+0.2 vs placeboNCT0117280840 other results
| 0.3 vs 0.1+0.2 vs placeboNCT0301206117 other results
|
| ACQ-5, change | —Not reported | —Trial running · NCT04651777 |
| OCS dose reduction | —Not reported | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- Tiotropium bromide
- —Not reported
- Umeclidinium
- —Trial running · NCT04651777
Trough FEV1, change
- Tiotropium bromide
- 0.1 vs -0.0+0.2 vs placeboNCT01172808
40 other results
- 0.2 vs -0.0 NCT01172821
- 0.1 vs 0.1 NCT00772538
- 0.1 vs -0.0 NCT01172808
- 0.1 vs -0.0 NCT01172821
- 0.2 vs 0.0 NCT00776984
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.3 vs 0.3 NCT01634139
- 0.1 vs 0.1 NCT01340209
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.1 vs 0.1 NCT00772538
- 0.4 vs 0.3 NCT01634139
- 0.2 vs 0.1 NCT00776984
- 0.2 vs 0.1 NCT01340209
- 0.2 vs -0.0 NCT02573155
- 0.1 vs -0.0 NCT02573155
- 0.5 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- -0.0 vs -0.0 NCT02573155
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.3 vs 0.1 NCT01152450
- 0.4 vs 0.3 NCT01122680
- 0.3 vs 0.1 NCT01152450
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
- Umeclidinium
- 0.3 vs 0.1+0.2 vs placeboNCT03012061
17 other results
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.3 vs 0.1 NCT03012061
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.0 NCT01641692
- 0.1 vs 0.1 NCT02164539
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.1 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.2 NCT01573624
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
ACQ-5, change
- Tiotropium bromide
- —Not reported
- Umeclidinium
- —Trial running · NCT04651777
OCS dose reduction
- Tiotropium bromide
- —Not reported
- Umeclidinium
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Tiotropium bromide: 9 of 9 rows · Umeclidinium: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Tiotropium bromide Rows use multiple source trials | Umeclidinium Rows use multiple source trials |
|---|---|---|
| Evening PEF absolute change · L/min | 1.101 vs -10.357 placebo L/min @ 52wk2.5 µg once dailya,b,c,d,e NCT01340209 · Phase 3 · registry result, not featured evidence show 1 more dose6.041 vs -10.357 placebo L/min @ 52wk5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence | 23.7 vs -5.2 FF L/min100 mcg + 125 mcga,b,c,d,e NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 4 more doses11.1 vs -5.2 FF L/min100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 17.7 vs -5.2 FF L/min100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 12.1 vs -5.2 FF L/min100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 16 vs -5.2 FF L/min100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 |
| FEV1 Trough absolute change · L No placebo or comparator arm | 0.207 L @ 4wk5 µg QDa,c,d,f NCT01696071 · Phase 2 · registry result, not featured evidence show 1 more dose0.203 L @ 4wk2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence | 0.0444 L @ 2wk100 mcg + 125 mcga,c,d,f NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 4 more doses0.026 L @ 2wk100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.051 L @ 2wk100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.032 L @ 2wk100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.0385 L @ 2wk100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 |
| Morning PEF absolute change · L/min | 24.31 vs 1.953 placebo L/min @ 4wk5 µg once dailya,g,d NCT01152450 · Phase 2 · registry result, not featured evidence show 1 more dose23.281 vs 1.953 placebo L/min @ 4wk2.5 µg twice daily NCT01152450 · Phase 2 · registry result, not featured evidence | 10.5 vs -14.2 FF L/min @ 4wk100/250 µga,g,d NCT02164539 · Phase 2 · registry result, not featured evidence · combination show 3 more doses5.5 vs -14.2 FF L/min @ 4wk100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 3.9 vs -14.2 FF L/min @ 4wk100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 7.6 vs -14.2 FF L/min @ 4wk100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Morning PEF absolute change · L | 26.362 vs 20.824 placebo L @ 48wk2.5 mcga,b,c,h,e NCT01634139 · Phase 3 · registry result, not featured evidence · add on show 1 more dose29.598 vs 20.824 placebo L @ 48wk5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on | 20 vs -2.9 FF L100 mcg + 125 mcga,b,c,h,e NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 4 more doses13 vs -2.9 FF L100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 19 vs -2.9 FF L100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 14.5 vs -2.9 FF L100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 15.7 vs -2.9 FF L100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 |
| Rescue Puffs absolute change · Puffs | -0.29 vs -0.25 placebo Puffs @ 52wk2.5 µg once dailya,b,g,d,i NCT01340209 · Phase 3 · registry result, not featured evidence show 1 more dose-0.22 vs -0.25 placebo Puffs @ 52wk5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence | -0.2 vs 0.6 FF Puffs @ 4wk100/250 µga,b,g,d,i NCT02164539 · Phase 2 · registry result, not featured evidence · combination show 3 more doses0 vs 0.6 FF Puffs @ 4wk100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination -0.4 vs 0.6 FF Puffs @ 4wk100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination -0.5 vs 0.6 FF Puffs @ 4wk100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 11%5 µg/dayj NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 4.4%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 3.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 8%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 4.4%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 7%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 7%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 8.7%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 4.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 5.1%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 3.2%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 1.9%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 9.6%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence | —100 mcg + 125 mcgk NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 5.9%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 2%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 5.1%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 9.3%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 6.5%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 5.8%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 2.5%5 µg/dayj NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 —2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on —5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.5%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0.9%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.8%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 3%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 0.8%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 1.3%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.9%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence | —100 mcg + 125 mcgk NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results—100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 —100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 7.6%5 µg/dayj NCT00772538 · Phase 3 show 39 more results1.5% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.2%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 1.5%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.6%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 2.2%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 1.5%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 3.5%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 3.5%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.9%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 1.5%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 2.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 2.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 8.7%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence 0%5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence 1%2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 1.4%5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 2.2%5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 0%2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%900 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 2.9%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%200 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%50 μg NCT02573155 · Phase 1 · registry result, not featured evidence | 0%100 mcg + 125 mcgk NCT01573624 · Phase 2 · combination · Asthma · phase 2 show 19 more results0%100 mcg + 15.6 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 250 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0.6%100 mcg + 31.25 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%100 mcg + 62.5 mcg NCT01573624 · Phase 2 · combination · Asthma · phase 2 0%31.25 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 —31.25 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0.7%250 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%125 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%62.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%31.5 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg BID NCT01641692 · Phase 2 · combination · Asthma · phase 2 0%15.6 µg QD NCT01641692 · Phase 2 · combination · Asthma · phase 2 2.9%31.25 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 2.2%62.5 mcg QD NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 5 µg/dayj asthma 34.6% (placebo 44.6%) peak expiratory flow rate decreased 20.7% (placebo 26.1%) nasopharyngitis 8% (placebo 9%) NCT00772538 · Phase 3 show 28 more resultsurgent care visit due to asthma 1% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.5 mcg asthma 36.3% (placebo 43.5%) peak expiratory flow rate decreased 23% (placebo 20.6%) nasopharyngitis 11.1% (placebo 9.9%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 34.1% (placebo 43.5%) peak expiratory flow rate decreased 21.5% (placebo 20.6%) respiratory tract infection 9.6% (placebo 12.2%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 14.7% (placebo 21.6%) peak expiratory flow rate decreased 11% (placebo 14.9%) nasopharyngitis 4.4% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 16.9% (placebo 21.6%) peak expiratory flow rate decreased 11.5% (placebo 14.9%) nasopharyngitis 4.6% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 21.6% (placebo 23.2%) nasopharyngitis 10.4% (placebo 12.3%) respiratory tract infection viral 8.8% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 5 mcg asthma 16.4% (placebo 23.2%) nasopharyngitis 14.9% (placebo 12.3%) respiratory tract infection viral 7.5% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 2.5 μg asthma 11% (placebo 10.4%) peak expiratory flow rate decreased 7.1% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 5 μg asthma 10.8% (placebo 10.4%) peak expiratory flow rate decreased 3.8% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 2.5 µg once daily nasopharyngitis 44.7% (placebo 42.1%) asthma 29.8% (placebo 36.8%) bronchitis 13.2% (placebo 7%) NCT01340209 · Phase 3 · registry result, not featured evidence 5 µg once daily nasopharyngitis 48.2% (placebo 42.1%) asthma 28.1% (placebo 36.8%) peak expiratory flow rate decreased 15.8% (placebo 21.1%) NCT01340209 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 13.7% (placebo 21.6%) peak expiratory flow rate decreased 10.7% (placebo 19%) nasopharyngitis 6.9% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 22.7% (placebo 21.6%) peak expiratory flow rate decreased 12.9% (placebo 19%) nasopharyngitis 8.3% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 17.1% (placebo 21.3%) nasopharyngitis 12.1% (placebo 10.2%) peak expiratory flow rate decreased 8.2% (placebo 11%) NCT01172821 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 19.8% (placebo 21.3%) peak expiratory flow rate decreased 9.9% (placebo 11%) nasopharyngitis 7.5% (placebo 10.2%) NCT01172821 · Phase 3 · registry result, not featured evidence 2.5 mcg asthma 15.6% (placebo 12.3%) peak expiratory flow rate decreased 5.8% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 mcg asthma 11% (placebo 12.3%) peak expiratory flow rate decreased 3.9% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 µg/day asthma 37.9% (placebo 47.9%) peak expiratory flow rate decreased 20.1% (placebo 27.4%) nasopharyngitis 14.6% (placebo 15.4%) NCT00776984 · Phase 3 · registry result, not featured evidence 2.5 µg once daily headache 7.8% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 5 µg once daily headache 5.6% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 2100 μg nasopharyngitis 40% (placebo 8.3%) bronchitis viral 20% (placebo 0%) feeling hot 20% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 16.7% (placebo 25%) nausea 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 9.7% (placebo 25%) chronic obstructive pulmonary disorder 3.2% (placebo 0%) nasopharyngitis 3.2% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 900 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) cough 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 14.7% (placebo 25%) chronic obstructive pulmonary disorder 5.9% (placebo 0%) nasopharyngitis 2.9% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 200 μg abscess oral 16.7% (placebo 0%) chest discomfort 16.7% (placebo 8.3%) chest pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 50 μg headache 50% (placebo 25%) nasopharyngitis 50% (placebo 8.3%) back pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence | show 18 more results31.25 µg BID headache 4.5% (placebo 1.6%) nasopharyngitis 1.5% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 250 µg QD headache 4.4% (placebo 1.6%) product taste abnormal 3.7% (placebo 0%) nasopharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 125 µg QD headache 3.1% (placebo 1.6%) product taste abnormal 3.1% (placebo 0%) nasopharyngitis 2.3% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 62.5 µg QD headache 3.8% (placebo 1.6%) pharyngitis 3.8% (placebo 0.8%) nasopharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.5 µg QD headache 2.9% (placebo 1.6%) product taste abnormal 1.4% (placebo 0%) pharyngitis 0.7% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg BID nasopharyngitis 3.2% (placebo 0.8%) headache 1.6% (placebo 1.6%) pharyngitis 0.8% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 15.6 µg QD headache 3.8% (placebo 1.6%) nasopharyngitis 2.3% (placebo 0.8%) pharyngitis 0% (placebo 0.8%) NCT01641692 · Phase 2 · combination · Asthma · phase 2 31.25 mcg QD nasopharyngitis 10.1% (placebo 11.9%) headache 6.5% (placebo 7.7%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 62.5 mcg QD nasopharyngitis 9.4% (placebo 11.9%) headache 8.6% (placebo 7.7%) upper respiratory tract infection 4.3% (placebo 2.1%) NCT03012061 · Phase 2 · registry result, not featured evidence · background therapy 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fAssessment timepoints differ: 4 weeks versus 2 weeks.
- gPopulation context differs: registered conditions differ.
- hTreatment context differs: add on versus combination.
- iAssessment timepoints differ: 52 weeks versus 4 weeks.
- jPopulation comparability has not been reviewed for 39 of these studies.
- kPopulation comparability has not been reviewed for 7 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tiotropium bromide
show 30 more results
show 7 more results
show 30 more results
show 28 more results
show 5 more results
show 22 more results
show 11 more results
show 11 more results
show 18 more results
show 1 more result
show 1 more result
+ 68 further endpoints in the CSV export.
Umeclidinium
show 6 more results
show 6 more results
show 5 more results
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Tiotropium bromide's landscape · Umeclidinium's landscape